1. Medtech Insight
  2. >>Geography
  3. >>Europe

Latest UK Political Shenanigans: What Medtech Needs To Know

 
• By Amanda Maxwell

Theresa May finally made a Brexit plan, but its effects have been explosive. One consequence: the UK has a new health secretary. What do the latest cabinet changes mean for health products, and why is certainty still so far away?

The Rt Hon Matt Hancock, Minister of State for Digital, talking at FinTech Night on 21 September 2017 at the British Embassy Tokyo. (c) British Embassy Tokyo (https://www.flickr.com/photos/uk-in-japan/26329373639)
Matt Hancock , pictured at a 2017 meeting in Tokyo, is the UK's new health secretary. He has previously led digital technology efforts in the UK. • Source: British Embassy Tokyo

Against an unstable and rapidly changing political backdrop fueled by Brexit, there has been an unexpected change in the UK government's health-sector leadership. Jeremy Hunt, who has served as health secretary since 2012, has been appointed the foreign secretary in Prime Minister Theresa May's new cabinet.

This is not a good time for the UK life sciences community to be losing the man in charge, just...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

The NHS England chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

EU/US Trade Deal Raises Questions For Medtech

 
• By Amanda Maxwell

There is still no clarity on how life sciences will be treated in the final agreement.

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By Ashley Yeo

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 
• By Amanda Maxwell

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

More from Geography

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

FDA ‘Regulatory Accelerator’ Aims To Speed Digital Health Development

 
• By Elizabeth Orr

The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.

From ‘Work Harder’ to ‘Phenomenal People’: Makary’s FDA About-Face

 
• By Michael McCaughan

In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.